Stay updated with breaking news from Pascal Touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced the Committee for Medicinal Products for Human Use (CHMP) of the...
Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Wednesday, MarketBeat.com reports. They currently have a $10.00 target price on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside […]
Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment IDSMC Did Not Identify Any Safety ConcernsPhase 2 Study Target Enrollment Achieved; Final Data and Communication Expected in October 2023Conference Call and Webcast Today at 2:00 p.m. PDT/5:00 p.m. EDTSOUTH...